157 related articles for article (PubMed ID: 28768504)
1. Geographic Variations and Time Trends in Cancer Treatments in Taiwan.
Hsu JC; Chang SM; Lu CY
BMC Public Health; 2017 Aug; 18(1):89. PubMed ID: 28768504
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal trends in use and costs of targeted therapies for common cancers in Taiwan: a retrospective observational study.
Hsu JC; Lu CY
BMJ Open; 2016 Jun; 6(6):e011322. PubMed ID: 27266775
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal trends in use of targeted therapies for treatment of malignant neoplasms of the eye: a population-based study in Taiwan.
Hsu JC; Gonzalez-Gonzalez LA; Lu VH; Lu CY
BMJ Open; 2016 May; 6(5):e010706. PubMed ID: 27235298
[TBL] [Abstract][Full Text] [Related]
4. Decision to adopt medical technology under the National Health Insurance System in Taiwan: case study of new molecular targeted drugs among non-small cell lung cancer patients.
Chen HL; Shen LJ; Wei CP; Lu HM; Hsiao FY
J Eval Clin Pract; 2015 Oct; 21(5):808-16. PubMed ID: 26096761
[TBL] [Abstract][Full Text] [Related]
5. Factors Affecting Usage Levels and Trends of Innovative Oncology Drugs Upon and After Reimbursement Under Taiwan National Health Insurance: Interrupted Time Series Analysis.
Liao KH; Ko BS; Chen LK; Hsiao FY
Clin Transl Sci; 2020 Nov; 13(6):1288-1297. PubMed ID: 32583962
[TBL] [Abstract][Full Text] [Related]
6. Disease and economic burden for rare diseases in Taiwan: A longitudinal study using Taiwan's National Health Insurance Research Database.
Hsu JC; Wu HC; Feng WC; Chou CH; Lai EC; Lu CY
PLoS One; 2018; 13(9):e0204206. PubMed ID: 30240449
[TBL] [Abstract][Full Text] [Related]
7. Use of cognitive enhancers and associated medical care costs among patients with dementia: a nationwide study in Taiwan.
Ku LJ; Pai MC
Int Psychogeriatr; 2014 May; 26(5):795-804. PubMed ID: 24429098
[TBL] [Abstract][Full Text] [Related]
8. Trend and geographic analysis of the prevalence of dengue in Taiwan, 2010-2015.
Hsu JC; Hsieh CL; Lu CY
Int J Infect Dis; 2017 Jan; 54():43-49. PubMed ID: 27865829
[TBL] [Abstract][Full Text] [Related]
9. Economic burden of adverse events in patients with metastatic renal cell carcinoma.
Hagiwara M; Borker R; Oster G
Clin Ther; 2013 Dec; 35(12):1955-1963.e2. PubMed ID: 24290735
[TBL] [Abstract][Full Text] [Related]
10. Patterns of combined prescriptions of aspirin-Ginkgo biloba in Taiwan: a population-based study.
Chang LC; Huang N; Chou YJ; Kao FY; Hsieh PC; Huang YT
J Clin Pharm Ther; 2008 Jun; 33(3):243-9. PubMed ID: 18452411
[TBL] [Abstract][Full Text] [Related]
11. Pricing appraisal of anti-cancer drugs in the South East Asian, Western Pacific and East Mediterranean Region.
Salmasi S; Lee KS; Ming LC; Neoh CF; Elrggal ME; Babar ZD; Khan TM; Hadi MA
BMC Cancer; 2017 Dec; 17(1):903. PubMed ID: 29282008
[TBL] [Abstract][Full Text] [Related]
12. Risk-adjusted resource allocation: using Taiwan's National Health Insurance as an example.
Chang HY; Bodycombe DP; Huang WF; Weiner JP
Asia Pac J Public Health; 2015 Mar; 27(2):NP958-71. PubMed ID: 23343643
[TBL] [Abstract][Full Text] [Related]
13. Changes in physicians' practice of prescribing cyclooxygenase-2 inhibitor after market withdrawal of rofecoxib: a retrospective study of physician-patient pairs in Taiwan.
Hsiao FY; Tsai YW; Huang WF
Clin Ther; 2009 Nov; 31(11):2618-27. PubMed ID: 20110006
[TBL] [Abstract][Full Text] [Related]
14. Recent trends in antibiotic prescriptions for acute respiratory tract infections in pediatric ambulatory care in Taiwan, 2000-2009: A nationwide population-based study.
Lee ML; Cho CY; Hsu CL; Chen CJ; Chang LY; Lee YS; Soong WJ; Jeng MJ; Wu KG
J Microbiol Immunol Infect; 2016 Aug; 49(4):554-60. PubMed ID: 25442862
[TBL] [Abstract][Full Text] [Related]
15. The economic burden of common adverse events associated with metastatic colorectal cancer treatment in the United States.
Latremouille-Viau D; Chang J; Guerin A; Shi S; Wang E; Yu J; Ngai C
J Med Econ; 2017 Jan; 20(1):54-62. PubMed ID: 27603498
[TBL] [Abstract][Full Text] [Related]
16. Assessing the effect of Taiwan's outpatient prescription drug copayment policy in the elderly.
Liu SZ; Romeis JC
Med Care; 2003 Dec; 41(12):1331-42. PubMed ID: 14668666
[TBL] [Abstract][Full Text] [Related]
17. Real-world costs and outcomes in metastatic renal cell carcinoma patients treated with targeted therapies: a cohort study from the French health insurance database.
Maroun R; Fleury L; Nachbaur G; Maunoury F; Vanhille JL; Durand-Zaleski I
Curr Med Res Opin; 2017 Oct; 33(10):1755-1762. PubMed ID: 28748721
[TBL] [Abstract][Full Text] [Related]
18. National trends in use and costs of oral anticancer drugs in France: An 8-year population-based study.
Bosco-Lévy P; de Boissieu P; Gouverneur A; Noize P; Molimard M; Fourrier-Réglat A; Bezin J
Pharmacoepidemiol Drug Saf; 2017 Oct; 26(10):1233-1241. PubMed ID: 28771878
[TBL] [Abstract][Full Text] [Related]
19. Cost-Effectiveness of Sorafenib Monotherapy and Selected Combination Therapy with Sorafenib in Patients with Advanced Hepatocellular Carcinoma.
Ho JC; Hsieh ML; Chuang PH; Hsieh VC
Value Health Reg Issues; 2018 May; 15():120-126. PubMed ID: 29704658
[TBL] [Abstract][Full Text] [Related]
20. Age- and gender-specific epidemiology, treatment patterns, and economic burden of osteoporosis and associated fracture in Taiwan between 2009 and 2013.
Wang CY; Fu SH; Yang RS; Shen LJ; Wu FL; Hsiao FY
Arch Osteoporos; 2017 Oct; 12(1):92. PubMed ID: 29067572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
